Association of rs11672691 PCAT19 / CEACAM and rs2987983 ESR2 polymorphisms with the possibility of prostate adenocarcinoma in Iranian population

Prostate cancer among men is the second most common cancer in terms of age-standardized incidence (ASR=16.6) and the third most common cancer in terms of mortality in Iran. The aim of this study was to investigate the association of rs11672691 PCAT19/CEACAM and rs2987983 ESR2 gene polymorphisms with the possibility of prostate adenocarcinoma in Iranian population.

In this case-control study (n=176), 87 men with prostate adenocarcinoma were examined as the case group and 97 men with benign prostatic hyperplasia (BPH) as the control group. Both groups had referred to Labafinejad Hospital in Tehran, Iran. Tetra-primer ARMS-PCR method was used to determine the genotype of each participant for rs11672691 (NC_000019.10) and rs2987983 (NC_000014.9) polymorphisms.

According to Fisher's exact test between the genotypic distribution of the two polymorphisms rs2987983 and rs11672691, there was no significant difference between the two groups of adenocarcinoma and BPH (P<0.05). A significant difference was observed between the genotype distribution of rs11672691 polymorphism and PSA>10 (P=0.028) and in other cases there was no association between different levels of PSA with these two polymorphisms.

The findings of this study reveal that the two polymorphisms rs11672691 and rs2987983 have no association with the risk of prostate cancer in the Iranian population.